JPMorgan Chase & Co. filed a Schedule 13G with the SEC on November 10, 2026, reporting beneficial ownership of 2,687,914 shares of Korsana Biosciences, Inc. common stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: JPMorgan Chase & Co. reported aggregate beneficial ownership of 2,687,914 shares of Korsana Biosciences common stock.
  • Percent of class: The reported holdings represent 5.9% of the issuer's outstanding common stock.
  • Sole voting and dispositive power: JPMorgan holds sole voting power and sole dispositive power over all 2,687,914 shares, with zero shared voting or dispositive power reported.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Relevant subsidiary ownership: According to the filing, 270 Life Sciences Private Capital Master Fund I SCA-RAIF is the beneficial owner of 5.0% of the issuer's common shares.
  • Filing subsidiaries identified: The filing identifies JPMorgan Asset Management (Europe) S.A.R.L. and J.P. Morgan Investment Management Inc. as the relevant subsidiaries through which the securities were acquired.

JPMorgan Chase Crosses 5% Threshold in Korsana Biosciences

JPMorgan Chase & Co., incorporated in Delaware and headquartered at 270 Park Avenue, New York, NY 10017, filed a Schedule 13G disclosing a 5.9% beneficial ownership position in Korsana Biosciences, Inc. (NASDAQ:KRSA). The filing was signed by Rachel Tsvaygoft, Vice President, on November 10, 2026, and the triggering event date was September 30, 2026. Korsana Biosciences is located at 245 First Street, 18th Floor, Cambridge, MA 02142, according to the filing.

The filing reports that JPMorgan Chase & Co. holds sole voting power and sole dispositive power over all 2,687,914 shares, with no shared voting or dispositive power reported. JPMorgan identified itself as a parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). The two subsidiaries identified in connection with this filing are JPMorgan Asset Management (Europe) S.A.R.L. and J.P. Morgan Investment Management Inc.

In response to Item 6, the filing states that "270 Life Sciences Private Capital Master Fund I SCA-RAIF is the beneficial owner of 5.0% of the issuer's common shares," indicating that another person has the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, more than 5% of the issuer's common shares. The filing's certification states the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

JPMorgan Chase & Co. disclosed beneficial ownership of 2,687,914 shares, or 5.9%, of Korsana Biosciences, Inc. common stock as of September 30, 2026, through two identified subsidiaries, with sole voting and dispositive power over the entire position.